139 related articles for article (PubMed ID: 18718574)
1. Regarding "N-acetyl cysteine as a glutathione precursor for schizophrenia--a double-blind, randomized, placebo-controlled trial".
Hashimoto K
Biol Psychiatry; 2008 Nov; 64(9):e1. PubMed ID: 18718574
[No Abstract] [Full Text] [Related]
2. N-acetyl cysteine as a glutathione precursor for schizophrenia--a double-blind, randomized, placebo-controlled trial.
Berk M; Copolov D; Dean O; Lu K; Jeavons S; Schapkaitz I; Anderson-Hunt M; Judd F; Katz F; Katz P; Ording-Jespersen S; Little J; Conus P; Cuenod M; Do KQ; Bush AI
Biol Psychiatry; 2008 Sep; 64(5):361-8. PubMed ID: 18436195
[TBL] [Abstract][Full Text] [Related]
3. Qualitative methods in early-phase drug trials: broadening the scope of data and methods from an RCT of N-acetylcysteine in schizophrenia.
Berk M; Munib A; Dean O; Malhi GS; Kohlmann K; Schapkaitz I; Jeavons S; Katz F; Anderson-Hunt M; Conus P; Hanna B; Otmar R; Ng F; Copolov DL; Bush AI
J Clin Psychiatry; 2011 Jul; 72(7):909-13. PubMed ID: 20868637
[TBL] [Abstract][Full Text] [Related]
4. NAC: first controlled trial, positive results.
James JS
AIDS Treat News; 1996 Jul; (no 250):1-3. PubMed ID: 11363634
[TBL] [Abstract][Full Text] [Related]
5. [N-Acetylcysteine: new possibilities to use an old substance].
Ahola T; Lapatto R
Duodecim; 1999; 115(4):375-9. PubMed ID: 11830885
[No Abstract] [Full Text] [Related]
6. Glutathione precursor, N-acetyl-cysteine, improves mismatch negativity in schizophrenia patients.
Lavoie S; Murray MM; Deppen P; Knyazeva MG; Berk M; Boulat O; Bovet P; Bush AI; Conus P; Copolov D; Fornari E; Meuli R; Solida A; Vianin P; Cuénod M; Buclin T; Do KQ
Neuropsychopharmacology; 2008 Aug; 33(9):2187-99. PubMed ID: 18004285
[TBL] [Abstract][Full Text] [Related]
7. The antioxidant N-acetyl-L-cysteine does not prevent hippocampal glutathione loss or mitochondrial dysfunction associated with status epilepticus.
Sleven HJ; Gibbs JE; Cock HR
Epilepsy Res; 2006 May; 69(2):165-9. PubMed ID: 16490347
[TBL] [Abstract][Full Text] [Related]
8. Placebo-controlled augmentation trials of the antioxidant NAC in schizophrenia: A review.
Chen AT; Chibnall JT; Nasrallah HA
Ann Clin Psychiatry; 2016 Aug; 28(3):190-6. PubMed ID: 27490835
[TBL] [Abstract][Full Text] [Related]
9. N-acetyl cysteine for the conversion of atrial fibrillation into sinus rhythm after cardiac surgery: a prospective, randomized, double-blind, placebo-controlled pilot study.
Ozaydin M; Erdogan D; Yucel H; Peker O; Icli A; Akcay S; Etli M; Ceyhan BM; Sutcu R; Varol E; Dogan A; Yavuz T
Int J Cardiol; 2013 May; 165(3):580-3. PubMed ID: 23041016
[No Abstract] [Full Text] [Related]
10. Glutathione precursor N-acetyl-cysteine modulates EEG synchronization in schizophrenia patients: a double-blind, randomized, placebo-controlled trial.
Carmeli C; Knyazeva MG; Cuénod M; Do KQ
PLoS One; 2012; 7(2):e29341. PubMed ID: 22383949
[TBL] [Abstract][Full Text] [Related]
11. N-acetylcysteine improves EEG measures of auditory deviance detection and neural synchronization in schizophrenia: A randomized, controlled pilot study.
Yang YS; Davis MC; Wynn JK; Hellemann G; Green MF; Marder SR
Schizophr Res; 2019 Jun; 208():479-480. PubMed ID: 30712814
[No Abstract] [Full Text] [Related]
12. [Strange but true: acetylcysteine protects against kidney damage caused by iodized contrast media].
Rizzato G
Radiol Med; 2001 Apr; 101(4):287-9. PubMed ID: 11398061
[No Abstract] [Full Text] [Related]
13. Effects of N-acetylcysteine on Pulmonary Functions in Patients with Systemic Sclerosis: A Randomized Double Blind, Placebo Controlled Study.
Mehrabi S; Moradi MM; Khodamoradi Z; Nazarinia MA
Curr Rheumatol Rev; 2020; 16(2):149-157. PubMed ID: 31830885
[TBL] [Abstract][Full Text] [Related]
14. Comments on "Short-term testosterone augmentation in male schizophrenics: a randomized, double-blind, placebo-controlled trial" by Dr Ko and colleagues.
Pae CU
J Clin Psychopharmacol; 2009 Apr; 29(2):194-5; author reply 196-7. PubMed ID: 19512992
[No Abstract] [Full Text] [Related]
15. Nail-biting stuff? The effect of N-acetyl cysteine on nail-biting.
Berk M; Jeavons S; Dean OM; Dodd S; Moss K; Gama CS; Malhi GS
CNS Spectr; 2009 Jul; 14(7):357-60. PubMed ID: 19773711
[TBL] [Abstract][Full Text] [Related]
16. Clinical trial of the anti-plaque activity of a mucolytic agent, N-Acetyl Cysteine.
Bowles WH; Goral V
Dent Hyg (Chic); 1985 Oct; 59(10):454-6. PubMed ID: 3908155
[No Abstract] [Full Text] [Related]
17. Potentially detrimental effects of N-acetylcysteine on renal function in knee arthroplasty.
Laisalmi-Kokki M; Pesonen E; Kokki H; Valta P; Pitkänen M; Teppo AM; Honkanen E; Lindgren L
Free Radic Res; 2009 Jul; 43(7):691-6. PubMed ID: 19526394
[TBL] [Abstract][Full Text] [Related]
18. Effect of N-acetylcysteine(NAC) treatment on HIV-1 infection: a double-blind placebo-controlled trial.
Akerlund B; Jarstrand C; Lindeke B; Sönnerborg A; Akerblad AC; Rasool O
Eur J Clin Pharmacol; 1996; 50(6):457-61. PubMed ID: 8858271
[TBL] [Abstract][Full Text] [Related]
19. Case 3-2007: a boy with respiratory insufficiency.
Grigg J; Cooke MS; Panickar JR
N Engl J Med; 2007 May; 356(22):2329-30; author reply 2330. PubMed ID: 17542074
[No Abstract] [Full Text] [Related]
20. N-acetylcysteine as a potentially useful medication to prevent conversion to schizophrenia in at-risk individuals.
Asevedo E; Cunha GR; Zugman A; Mansur RB; Brietzke E
Rev Neurosci; 2012; 23(4):353-62. PubMed ID: 22944654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
